RNA-based therapeutic solutions against viral threats
At Avocet Bio, our mission is clear: we want to break new ground by using RNA-based RNA modulation as key therapeutic option based on our platform technology.
Today, innovations in RNA-based technologies are emerging as key tools in the fight against a wide range of diseases. As a biotech startup, we address some of the most pressing global health challenges, including respiratory viral infections and are exploring RNA modulation for use in other areas such as chronic lung diseases and cardiovascular medicine.
Our technology holds the potential to reshape how viral infections are treated, offering a new frontier in antiviral therapies where we can directly stop the replication of viruses in their tracks. Our focus extends beyond single virus targets; we are developing a versatile platform that can be rapidly adapted to address emerging and evolving viral threats, creating flexible treatments that are able to handle pandemics and seasonal outbreaks alike.
Our vision includes the expansion of our platform’s applicability to multiple RNA viruses, and beyond antiviral applications.
Using RNA-editing, we are able to respond to viral threats with precise, scalable solutions that exert broad-spectrum antiviral activity by effectively inhibiting viral replication of any RNA virus family. This flexibility ensures that we can stay ahead of viral mutations. As a result, we can quickly develop solutions for new variants and address future viral threats effectively.
Recognizing the immense potential of RNA modulation, we are actively exploring its use in RNA-based therapies to address a variety of medical challenges. By modulating RNA processes, we aim to create therapeutic solutions that can influence cellular pathways involved in various diseases.
To date, we have achieved preclinical proof of concept with our antiviral product candidates and we plan to launch additional programs that can benefit from our platform technology approach. We have developed a suitable formulation for inhalable mRNA administration, which has been successfully tested in collaboration with industry partners. Targeting the lungs as the primary organ for delivery offers great promise for the rapid advancement of our antiviral products, as well as for the use of RNA therapeutics administered via inhalation.
Our long-term goal is to build a diverse portfolio of RNA-based therapeutics that address existing treatment gaps and offer new, more effective solutions for patients.
To support our growth and achieve our ambitious goals, we are committed to diversifying our platform. Through strategic partnerships and targeted expansion of our research and development efforts, we aim to accelerate the clinical development of RNA-based therapeutics and bring them to market.
As a young biotech company, we recognize the importance of strategic partnerships. We actively seek partnerships and funding opportunities to accelerate the development of our RNA-based treatments. We are focused on collaborating with strategic industry partners and securing financial support to advance our programs into clinical trials.
Please get in touch with us and visit our website for further information.